

Applicant: Graham P. Allaway et al.  
Serial No: 09/852,238  
Filed: May 9, 2001  
Page 3

In response, applicants submit a substitute paper copy of the Sequence Listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a computer readable form (CRF) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as **Exhibit C** a statement in accordance with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" attached as Exhibit B and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone either of them at the number provided below.


No fee is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Spencer H. Schneider  
Registration No. 45,923  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 8-1-01  
John P. White Date  
Reg. No. 28,678  
Spencer H. Schneider  
Reg. No. 45,923

## EXHIBIT B



#4

## SEQUENCE LISTING

<110> Graham P. Allaway et al.

<120> USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION

<130> 2048/51320-AB/JPW/SHS

<140> 09/852,238

<141> 2001-09-05

<160> 30

<170> PatentIn version 3.0

<210> 1

<211> 38

<212> DNA

<213> artificial

<400> 1

caaggctact tccctgattg gcagaactac acaccagg  
38

<210> 2

<211> 25

<212> DNA

<213> artificial

<400> 2

agcaagccga gtcctgcgctc gagag  
25

<210> 3

<211> 23

<212> DNA

<213> artificial

<400> 3

gggactttcc gctggggact ttc  
23

<210> 4

<211> 33

<212> DNA

<213> artificial

<400> 4  
cctgttcggg cgccactgct agagattttc cac  
33

<210> 5  
<211> 31  
<212> PRT  
<213> human

<400> 5

Met Asp Tyr Gln Val Ser Ser Pro Ile Tyr Asp Ile Asn Tyr Tyr Thr  
1 5 10 15

Ser Glu Pro Cys Gln Lys Ile Asn Val Lys Gln Ile Ala Ala Arg  
20 25 30

<210> 6  
<211> 15  
<212> PRT  
<213> human

<400> 6

His Tyr Ala Ala Ala Gln Trp Asp Phe Gly Asn Thr Met Cys Gln  
1 5 10 15

<210> 7  
<211> 32  
<212> PRT  
<213> human

<400> 7

Arg Ser Gln Lys Glu Gly Leu His Tyr Thr Cys Ser Ser His Phe Pro  
1 5 10 15

Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu Lys Ile Val  
20 25 30

<210> 8  
<211> 17  
<212> PRT  
<213> human

&lt;400&gt; 8

Gln Glu Phe Phe Gly Leu Asn Asn Cys Ser Ser Ser Asn Arg Leu Asp  
 1 5 10 15

Gln

&lt;210&gt; 9

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; artificial

&lt;400&gt; 9

aagcttggag aaccagcggg taccatggag gggatc  
 36

&lt;210&gt; 10

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; artificial

&lt;400&gt; 10

gtctgagtct gagtcaagct tggagaacca  
 30

&lt;210&gt; 11

&lt;211&gt; 41

&lt;212&gt; DNA

&lt;213&gt; artificial

&lt;400&gt; 11

ctcgagcatc tgtgttagct ggagtgaaaa cttgaagact c  
 41

&lt;210&gt; 12

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; artificial

&lt;400&gt; 12

gtctgagtct gagtccctcga gcattctgtgt  
 30

<210> 13  
<211> 32  
<212> DNA  
<213> artificial

<400> 13  
aagcttcaga gagaagccgg gatggaaact cc  
32

<210> 14  
<211> 30  
<212> DNA  
<213> artificial

<400> 14  
gtctgagtct gagtcaagct tcagagagaa  
30

<210> 15  
<211> 32  
<212> DNA  
<213> artificial

<400> 15  
ctcgagctga gtcagaaccc agcagagagt tc  
32

<210> 16  
<211> 30  
<212> DNA  
<213> artificial

<400> 16  
gtctgagtct ggtcctcga gctgagtcag  
30

<210> 17  
<211> 32  
<212> DNA  
<213> artificial

<400> 17  
aagcttcagt acatccacaa catgctgtcc ac  
32

<210> 18  
<211> 30  
<212> DNA  
<213> artificial

<400> 18  
gtctgagtct gagtcaagct tcagtacatc  
30

<210> 19  
<211> 31  
<212> DNA  
<213> artificial

<400> 19  
ctcgagcctc gttttataaa ccagccgaga c  
31

<210> 20  
<211> 30  
<212> DNA  
<213> artificial

<400> 20  
gtctgagtct gattcctcga gcctcgtttt  
30

<210> 21  
<211> 29  
<212> DNA  
<213> artificial

<400> 21  
aagcttcagg gagaagtga atgacaacc  
29

<210> 22  
<211> 30  
<212> DNA  
<213> artificial

<400> 22

gtctgagtct gagtcaagct tcagggagaa  
30

<210> 23  
<211> 33  
<212> DNA  
<213> artificial

<400> 23  
ctcgagcaga cctaaaacac aatagagagt tcc  
33

<210> 24  
<211> 30  
<212> DNA  
<213> artificial

<400> 24  
gtctgagtct gagtccctga gcagacctaa  
30

<210> 25  
<211> 34  
<212> DNA  
<213> artificial

<400> 25  
aagcttctgt agagttaaaa aatgaacccc acgg  
34

<210> 26  
<211> 30  
<212> DNA  
<213> artificial

<400> 26  
gtctgagtct gagtcaagct tctgtagagt  
30

<210> 27  
<211> 34  
<212> DNA  
<213> artificial



<400> 27  
ctcgagccat ttcatttttc tacaggacag catc  
34

<210> 28  
<211> 30  
<212> DNA  
<213> artificial

<400> 28  
gtctgagtct gagtcctcga gccatttcat  
30

<210> 29  
<211> 39  
<212> DNA  
<213> artificial

<400> 29  
gtctgagtct gagtcaagct taacaagatg gattatcaa  
39

<210> 30  
<211> 39  
<212> DNA  
<213> artificial

<400> 30  
gtctgagtct gagtcctcga gtccgtgtcg caagcccac  
39

# EXHIBIT C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Graham P. Allaway, et al.

Serial No. : 09/852,238

Filed : May 9, 2001

For



USES OF A CHEMOKINE RECEPTOR FOR  
INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas  
New York, New York 10036  
August 1, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing" and contains no new matter.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Spencer Schneider", written over a horizontal line.

Spencer Schneider  
Registration No. 45,923  
c/o Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400